The percentage of CCR2+ monocytes in MS patients was significantly higher than in healthy subjects (Figure 8A), which is in agreement with their higher percentage of classical inflammatory CD14++CD16− monocytes (Figure 2). This evidence concerns the gene CD14 and myeloid sarcoma.